Comparative effectiveness and safety of glargine 300 U/mL versus degludec 100 U/mL in insulin-naïve patients with type 2 diabetes. A multicenter retrospective real-world study (RESTORE-2 NAIVE STUDY).

"Declarations Conflict of interestGPF has received consultancy of lecture fees from Abbott, AstraZeneca, Boehringer, Lilly, MSC, NovoNordisk, Mundipharma, Sanofi, Servier and Takeda. RB has received consultancy of lecture fees from Abbott, AstraZeneca, Lilly, NovoNordisk, Mundipharma and Sanofi. ML is an employee of Sanofi and may hold shares and/or stock options in the company. MCR and AN have received funding for research from Sanofi, NovoNordisk, Alfasigma, Artsana, AstraZeneca, Johnson&Johnson, Medtronic, Shionogi, SOBI, Meteda and Theras. DC has received consultation fees and speaker honoraria from Eli Lilly, Novo Nordisk, Roche Diagnostics, Sanofi and Takeda. Human and animal rightsAll procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. The study protocol was approved by all local ethics committees of the participating centers. Informed consentInformed consent was obtained from all patients for being included in the study. Conflict of interest GPF has received consultancy of lecture fees from Abbott, AstraZeneca, Boehringer, Lilly, MSC, NovoNordisk, Mundipharma, Sanofi, Servier and Takeda. RB has received consultancy of lecture fees from Abbott, AstraZeneca, Lilly, NovoNordisk, Mundipharma and Sanofi. ML is an employee of Sanofi and may hold shares and/or stock options in the company. MCR and AN have received funding for research from Sanofi, NovoNordisk, Alfasigma, Artsana, AstraZeneca, Johnson&Johnson, Medtronic, Shionogi, SOBI, Meteda and Theras. DC has received consultation fees and speaker honoraria from Eli Lilly, Novo Nordisk, Roche Diagnostics, Sanofi and Takeda."

"Funding The study was funded by Sanofi S.r.l., Milan, Italy."